Eyenovia, Inc.

Greetings and welcome to the iNovia second quarter 2022 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I will now turn the conference over to Eric Ribner of Lifetime Advisors. Please go ahead, sir.

Thanks very much, and good afternoon, and welcome to Inovia's second quarter 2022 earnings call and audio webcast. With me today are Inovia's chairman, Dr. Sean Ian Shulev, Chief Executive Officer Michael Rowe, and Chief Financial Officer John Gandolfi. This afternoon, Inovia issued a press release announcing financial results for the three-month end of June. 2022. We encourage everyone to read today's press release as well as Inovia's annual report on Form 10-K for the year ended December 31st, 2021, which was filed by the SEC March 30th, 2022, and our most recently filed 10-Q. The company's press release and annual report are also available on Inovia's website at www.inovia.com. In addition, this conference call is being webcast through website and will be archived there for future reference. Please note, on today's call, we will be discussing investigational products today, which have not yet to receive FDA approval. Please also note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, Inovia's management will be making forward statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are subject to a number of risks, which are described in more detail in our annual report on Form 10-K and most recently filed 10-Q. This conference call contains time-sensitive information and is accurate only as of the date of this live broadcast, August 10, 2022. INOVIA undertakes no obligation to revise or update any forward-looking statements, select events, or circumstances after the date of the conference call, except be required by applicable securities law. With that said, I'd like to turn the call over to Dr. Sean Ianchulev, Chairman of INOVIA's Board of Directors. Sean?

Thank you, Eric, and welcome everyone to our second quarter 2022 Financial Results Conference call. I'll keep my comments very brief this morning before handing the call over to Inovia's new CEO, Michael Rowe, for a comprehensive update. In June, I announced that I would be stepping down from both the CEO and chief medical officer roles and transitioning to chairman of the board, while also serving as a medical consultant to the company. At that time, the board retained an executive search firm and conducted a broad search for the most qualified candidates. We identified several potential candidates and conducted interviews. At the end of the day, however, the board agreed that none were better matched for the skill set we require right now than Michael Rowe. The appointment of Michael, who previously served as our chief operating officer, ensures continuity while at the same time bringing significant diverse ophthalmic industry operations and commercialization expertise to the CEO role. This is a critical moment given where we as a company stand today. We will be resubmitting our Midcombi new drug application in the fourth quarter, giving us line of sight to transitioning into a commercial stage company. At the same time, we're about to wrap up our second phase three presbyopia study, Vision 2, which will be one input of MicroLine NDA for what we estimate to be a multi-billion dollar presbyopia market in the U.S. alone. My goal was also instrumental in brokering our collaborations with Bausch and Lomb, the eye care business that was spun out of Bausch Health in 2021, and Arctic Vision. Together, these agreements provide us with potential sources of non-dilutive funding in the form of development and regulatory milestones, and if the respective products are approved, sales royalties. This could be significant over time. and we see opportunities for additional agreements in other territories. Given Michael's track record here, the board of directors has also voted to add Michael as a board member where we will be well served by his experience. With my transition to chairman, I will be able to continue to work with the board and leadership team to help guide Inovia towards its long-term goals while also remaining involved in future innovation as we work to expand our technology across additional therapeutic areas and cement our place as the new standard of care in topical ophthalmic therapies with the OptiJet device. This is a very exciting time for Inovio. And with Michael assuming the CEO role, I believe we have a world-class team in place to best position us for long-term success. This will benefit not only patients and physicians, but our shareholders as well. Remaining on the topic of leadership, last month we announced that we added Drs. Ellen Strauman and Ram Palanki as new directors to our board of directors. Each brings decades of medical technology, clinical development, launch and commercialization experience, much of it specific to ophthalmology. This cross-functional expertise rounds out what I believe to be a top quality board, especially at a time when we have these significant clinical, and regulatory milestones rapidly approaching. That Ellen and Ram have agreed to join our board provides strong validation of our technology, and I look forward to working with them and the entire board as we shepherd the company through this new and exciting phase of growth. At this point, I'd like to pass the baton over to Michael.